BSD's MicroThermX microwave ablation system available in Europe
This article was originally published in Clinica
BSD Medical has CE marked its MicroThermX microwave ablation system (MTX-180) for sale in Europe. The device is designed to treat cancer by using microwave energy to ablate soft tissue, delivered via a single-use disposable antenna. MTX-180 received 510(k) clearance from the US FDA in August (www.clinica.co.uk, 19 August 2010). Salt Lake City, Utah-based BSD estimates that the worldwide soft tissue ablation oncology market will reach $2bn.